People | May 01, 2026
Microbot Medical Inc. appoints Alon Tamir as VP Sales EMEA
Tamir brings more than 20 years of experience in the medical technology sector
Tamir brings more than 20 years of experience in the medical technology sector
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Patalganga plant received zero observation from USFDA earlier
The agreement could rise to $900 million if key commercial milestones are met
Acquisition enhances integrated pharmacovigilance platform, combining AI, automation, and services to improve compliance, efficiency, and end-to-end clinical safety operations
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
Subscribe To Our Newsletter & Stay Updated
